Great News! IVRS and Succipro Secure Eurostars Funding to Advance Next-Generation Treatment for Crohn’s Disease
We’re proud to share that IVRS AB and Succipro S.L. have received Eurostars funding to develop a new biologic therapy for Crohn’s disease, an important step toward more precise and effective treatments for inflammatory bowel disease (IBD). This collaboration brings together Succipro’s expertise in biologic drug development and IVRS’s advanced in vivo imaging capabilities, creating […]
IVRS and the NIAC Consortium Receive a Prestigious Eurostars Grant for Drug Development on Renal Cell Carcinoma
Exciting news! IVRS AB is proud to be a key partner in the NIAC consortium, recently awarded a €1.36M Eurostars grant for groundbreaking renal cell carcinoma (RCC) research! We’ll be leveraging our cutting-edge in vivo RCC models and whole-body 3D imaging to evaluate a novel inhibitor developed by AtG Therapeutics. This promising therapeutic could offer new hope for […]
New segment model on human lung cancer
We are thrilled to launch our new model of Non-Small Cell Lung Cancer. We use patient-derived xenografts as well as mouse allografts to replicate clinical features of this devastating condition. Join us today on our quest for accelerating preclinical drug discovery and combating lung cancer. Explore this and other segment models here: https://ivrs.se/segment-models/ If you have […]
IVRS is honored to receive the Branschvinnare i Sverige AB award for our dedication to excellence in the industry
We proudly announce that IVRS AB has been appointed to Industry Winner 2024 within Biotechnical Research and Development! Branschvinnare i Sverige AB awards this title to companies that have surpassed industry standards in both revenue and results. In 2024, only 14% of companies in Sweden are awarded this title. Visit our website to find out […]
Fantastic news! IVRS AB has received a Nordiskt Tillväxtcertifikat
We continue growing!
